DWA
CLDX icon

Dorsey Wright & Associates’s Celldex Therapeutics CLDX Stock Holding History

Dorsey Wright & Associates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-760
Closed -$13K – 291
2020
Q4 		$13K Buy
+760
New +$13.7K ﹤0.01% 260

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Dorsey Wright & Associates's CLDX Position: Q1 2021 in Review

Dorsey Wright & Associates sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 760 shares — an estimated $13K sold.

Dorsey Wright & Associates first reported a position in CLDX in Q4 2020 and held it in 1 quarter. The position peaked at $13K in Q4 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

  • Dorsey Wright & Associates reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 760 Celldex Therapeutics shares in Q1 2021, an estimated $13K.
  • Dorsey Wright & Associates first reported a position in Celldex Therapeutics in Q4 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Celldex Therapeutics position peaked at $13K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on Dorsey Wright & Associates's 13F filing for Q1 2021, filed 27 Apr 2021.